On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease – The multi-center T-SPARCLE registry study
| Autor: | Yen-Wen Wu, Wei-Hsian Yin, Wei-Kung Tseng, Jaw Wen Chen, Chau-Chung Wu, Fang-Ju Lin, L.-T. Ho, Yi-Heng Li, Hung-I Yeh |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Population Taiwan 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Internal medicine Secondary Prevention Humans Medicine Mass index Registries cardiovascular diseases 030212 general & internal medicine Renal Insufficiency Chronic education Dialysis Aged Proportional Hazards Models Aged 80 and over lcsh:R5-920 education.field_of_study business.industry Proportional hazards model Anticholesteremic Agents Incidence Incidence (epidemiology) Cholesterol LDL General Medicine Middle Aged Atherosclerosis medicine.disease Cardiovascular Diseases Heart failure Female Hydroxymethylglutaryl-CoA Reductase Inhibitors lcsh:Medicine (General) business Mace Kidney disease |
| Zdroj: | Journal of the Formosan Medical Association, Vol 117, Iss 9, Pp 814-824 (2018) |
| ISSN: | 0929-6646 |
| DOI: | 10.1016/j.jfma.2018.05.020 |
| Popis: | Background: The aim of this study is to determine the relationship between the on-treatment lipid profiles and the CV events in CKD and non-CKD population. Method: This study was a multi-center observational registry, the Taiwanese Secondary Prevention for patients with AtheRosCLErotic disease (T-SPARCLE) Registry. This study follows up patients with CV diseases in Taiwan who have secondary prevention therapies. The primary outcome is the time of first occurrence of a major adverse cardiac events (MACEs). Result: 5388 patients with ASCVD were included and 1478 (27.4%) had CKD without dialysis. CKD patients had higher TG and lower LDL-C levels. The incidence of recurrent MACEs per 1000 person-years in CKD patients was 19.5 (95% CI 15.5–24.9), compared with 9.1 (95% CI 7.4–11.1) in non-CKD patients. In patients with statin therapy, there were no differences in MACE risk between each level of on-treatment LDL-C, TG and HDL-C level. Higher on-treatment non-HDL-C level was a significant predictor for higher MACE risk in patients without CKD, and borderline significant in CKD patients under statin therapy. Heart failure history was also associated with higher MACE risk in both group. Lower body mass index (BMI |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|